Overview

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Status:
RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
Phase:
PHASE3
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Treatments:
Dexmedetomidine
Saline Solution